Heart disease risk: why the calculator is just the start

Clinical Rounds, the GPAtlas podcast. Cardiovascular. 8 minutes. Published 18 September 2026. Free to listen.

Clinical source: our own Ocean article "Cardiovascular Disease (CVD) Risk Assessment and Management", last reviewed 28 August 2026.

Transcript

Sarah: Hello, and welcome to GPAtlas Clinical Rounds. I am Sarah, and today Ben and I are diving into the practicalities of Cardiovascular Disease risk assessment and management in primary care, specifically looking at how we use our risk tools, when we bypass them, and how to have the most effective shared decision-making conversations with our patients.

Ben: Let us set the scene with a patient I saw earlier this week. He is a 52-year-old man, a local teacher, who came in for his routine NHS Health Check. He is a current smoker, smokes about ten cigarettes a day, and has a family history of a father who had a myocardial infarction at 58. On examination, his blood pressure was 142/92, his body mass index was 29, and his pulse was regular. When we spoke about his lifestyle, he was quite open about his diet being far from ideal, but he was very resistant to the idea of starting a daily tablet, saying he felt perfectly healthy and did not want to become a patient before he had to. He had read online that these risk calculators are just guessing games. This really highlights the challenge we face daily: how to balance the clinical data, like his QRISK3 score, with the patient's own perspective on his health, and knowing exactly where the threshold sits for meaningful intervention versus just checking boxes. It is not just about the percentage, but about making sure we identify those who truly benefit from intervention without medicalising those who do not, or worse, missing the opportunity to intervene early in someone who appears low-risk on paper but high-risk in reality.

Sarah: That is a perfect starting point, Ben, because the workup here is about so much more than just the output of the QRISK3 tool. Before we even plug the numbers in, we have to perform a thorough clinical assessment to see if this patient even belongs in the calculator or if they are high-risk by definition. I always start by explicitly excluding established cardiovascular disease, diabetes, or chronic kidney disease, as those patients bypass the tool entirely. Then, we need to consider those nuances that the calculator might miss. Are they on HIV treatment? Do they have a chronic inflammatory condition like rheumatoid arthritis or systemic lupus erythematosus? Are they on regular corticosteroids or atypical antipsychotics? These are all markers that raise the patient's actual risk beyond what the simple algorithm suggests. In your patient, the workup involves the lipid profile, which we should do non-fasting unless his triglycerides are over 4.5, an HbA1c to screen for undiagnosed type 2 diabetes, and renal function with a baseline eGFR. I also like to check liver function tests before we even have the conversation about statins, as it sets the scene for baseline monitoring. We must examine them properly, checking both arms for blood pressure, assessing waist circumference as a measure of central adiposity, and looking for those stigmata of hyperlipidaemia like xanthelasma or corneal arcus, even if they are rare. We should also ask about erectile dysfunction, which is such a powerful, under- reported predictor of vascular health. When we have the results, we are looking to see if he qualifies as high risk by default. If his total cholesterol was over 9, or his non-HDL was over 7.5, he would need specialist assessment regardless of any calculator score. Similarly, if there was a strong suggestion of familial hypercholesterolaemia, we would steer away from the calculator and towards a specialist lipid clinic. The workup is our filter, and we must be diligent, because if we rely solely on the machine, we might miss the patient who actually needs an earlier, more robust intervention than the 10-year risk percentage implies.

Ben: On Monday morning, the most important thing I do differently is how I handle the 'safe' QRISK3 score. We have all seen it: a patient comes in with a score of 6 percent, and we breathe a sigh of relief and send them on their way with a pat on the back. The change in practice here is recognising that for many patients, that number is a dangerous reassurance. If a patient is a recently stopped smoker, or has severe mental illness, or has a chronic inflammatory condition, the QRISK3 tool often underestimates their risk. In these cases, the number is not the end of the conversation, it is just a starting point for clinical judgement. I have stopped using the 10 percent threshold as a binary 'yes or no' for atorvastatin 20 mg. Instead, I focus on the absolute benefit. I talk to the patient about the number needed to treat. If their risk is 10 percent, the number needed to treat is about 25 over 10 years, which is a tangible way of explaining the benefit of the medication. The common failure I see is simply giving the patient the percentage and waiting for them to react, rather than translating that into what it means for their long- term health. We also need to be much more systematic with the follow-up. A statin is not a set-and-forget intervention. We need that 3-month lipid check, aiming for a 40 percent reduction in non-HDL cholesterol. If we are not seeing that, we do not just accept it; we check adherence, we look at their lifestyle again, and then we think about escalation. And please, let us stop being so nervous about minor LFT bumps. Unless those transaminases are persistently over 3 times the upper limit of normal, we do not need to stop the medication. The most common error I see in practice is stopping the statin for a minor, transient liver enzyme rise that is clinically insignificant, or failing to initiate the conversation at all because we are worried about side effects that the patient has read about on the internet. We need to be the voice of reason: show them the risk, show them the NNT, and support them in making an informed choice.

Sarah: The biggest pitfall, without a doubt, is the failure to distinguish between 10-year risk and lifetime risk, especially in our younger patients. If you have a 35-year-old patient who smokes and has a family history, their 10-year QRISK3 score will likely be very low, maybe 1 or 2 percent. If you rely on that, you are telling a 35-year-old that they are 'low risk', which is fundamentally untrue. Their 10-year risk might be low, but their lifetime risk of a major cardiovascular event is high, and they will likely cross the treatment threshold while they are still in their 40s or 50s. We need to be using lifetime risk tools for these patients to have an honest conversation about the future. It is about shifting the focus from 'what is my risk today' to 'what will my risk be if I keep doing what I am doing'. Another major pitfall is the 'high-risk by definition' group. We occasionally see GPs trying to calculate a score for a patient with established chronic kidney disease or familial hypercholesterolaemia. You simply should not do this. They have already qualified for primary or secondary prevention strategies based on their pathology. Using a risk calculator for these patients is a distraction and can lead to inappropriate delaying of treatment. Finally, be very careful with the 'lifestyle advice' bucket. We tell everyone to exercise more and eat a Mediterranean diet, but if we do not document specific, personalised advice and set follow-up targets, it becomes white noise. The patient hears 'lose weight and eat better' as a vague suggestion, not as a medical intervention that is as important as the statin they are trying to avoid. We need to frame lifestyle change as a proactive, measurable treatment in its own right, otherwise, we are just ticking boxes.

Sarah: To recap, here are three things to take away for your consultations on Monday. First, know who bypasses the QRISK3 calculator entirely; if they have established cardiovascular disease, chronic kidney disease, or are at high risk due to conditions like familial hypercholesterolaemia, do not use the tool, just start the pathway. Second, look beyond the 10-year percentage; always consider lifetime risk for younger patients and remember that clinical judgement must override a low score in patients with inflammatory disease, mental health conditions, or those who have recently stopped smoking. Third, make your follow-up meaningful; at the 3-month mark, check the non-HDL reduction, ensure the patient is actually taking the atorvastatin 20 mg, and only escalate or stop based on persistent, significant blood result changes, not transient ones.

Ben: Thanks for joining us today. Keep those conversations patient-centred, focus on the absolute benefits, and we will see you next time on GPAtlas Clinical Rounds.

More from Clinical Rounds

Every episode of Clinical Rounds, free to listen with a full transcript.